Bausch + Lomb's product portfolio, particularly its prescription Dry Eye Disease (DED) offerings, has been a focal point for investors and analysts. The company's newest DED drug, Miebo ...

Analysts estimate that FX headwinds could impact financial results by approximately $20-25 million in the coming quarters. Bausch + Lomb's product portfolio, particularly its prescription Dry Eye ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ... can occur in the late stages of dry aged-related macular degeneration ...

Learn more about whether Bausch + Lomb Corporation or Inari Medical, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Bausch & Lomb Corp.’s stock soared 10% early ... Growth was driven by higher sales of Lumify eye drops, Eye Vitamins and Dry Eye Portfolio in the consumer eye-care business and higher sales ...